A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting.

导出 OA

翻译打印收藏纠错

作者： Martin,Boegemann ^[1] ; Katrin,Schlack ^[1] ; Lena,Früchtenicht ^[1] ; Julie,Steinestel ^[2] ; Andres Jan,Schrader ^[1] ; Yvonne,Wennmann ^[1] ; Laura-Maria,Krabbe ^[1] ; Okyaz,Eminaga ^[3]

作者单位： Department of Urology, University of Muenster Medical Center, Muenster, Germany. ^[1] Department of Urology, Augsburg Medical Center, Augburg, Germany. ^[2] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. ^[3] Department of Urology, Stanford Medical School, Stanford, CA, USA. ^[4]

关键词 abiraterone mCRPC outcome risk score survival

DOI 10.18632/oncotarget.27133

PMID 31489117

发布时间 2020-02-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Oncotarget

2019年10卷49期

5082-5091页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除